Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients

Journal of Hypertension

Volumn 24, Issue 7, 2006, Pages 1397-1403

  Kaiser, Thomas ^a   Heise, Tim ^b,c   Nosek, Leszek ^b   Eckers, Uta ^b   Sawicki, Peter T ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b Profil Institut fuer Stoffwechselforschung GmbH   (Germany)

^c DIeM Inst for Evidence Based Med   (Germany)

Author keywords

Adrenergic beta antagonists; Angiotensin converting enzyme inhibitors; Glucose clamp technique; Insulin resistance

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; INSULIN; METOPROLOL; NEBIVOLOL; STEROID;

ADULT; ARTERY COMPLIANCE; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEADACHE; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNEE MENISCUS RUPTURE; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 33745444939     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000234121.48272.67     Document Type: Article

References (52)

1. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053-1059.
2. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
3. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868-873.
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
5. Wikstrand J. Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J 1988; 116:338-347.
6. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298:1152-1157.
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
8. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94:1172-1179.
9. Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998; 32:243-248.
10. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999; 48:821-827.
11. Tsuchiya M, Suzuki E, Egawa K, Nishio Y, Maegawa H, Inoue S, et al. Stiffness and impaired blood flow in lower-leg arteries are associated with severity of coronary artery calcification among asymptomatic type 2 diabetic patients. Diabetes Care 2004; 27:2409-2415.
12. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.
13. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med 2001; 250:11-17.
14. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G, et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 1995; 25:595-600.
15. Helgeland A, Leren P, Foss OP, Hjermann I, Holme I, Lund-Larsen PG. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study. Am J Med 1984; 76:802-805.
16. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982; 248:2004-2011.
17. Jacob S, Henriksen EJ. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens 2004; 6:690-696.
18. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955-959.
19. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14:489-494.
20. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274:1067-1071.
21. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19:1429-1435.
22. Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11:753-757.
23. Gans RO, Bilo HJ, Nauta JJ, Popp-Snijders C, Heine RJ, Donker AJ. The effect of angiotensin-I converting enzyme inhibition on insulin action in healthy volunteers. Eur J Clin Invest 1991; 21:527-533.
24. Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003; 4:197-203.
25. O'Rourke MF, Gallagher DE. Pulse wave analysis. J Hypertens 1996; 14(Suppl.):S147-S157.
26. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38:199-204.
27. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 1993; 14:160-167.
28. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95:1827-1836.
29. Wilkinson IB, MacCallum H, Rooijmans DF, Murray GD, Cockcroft JR, McKnight JA, et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM 2000; 93:441-448.
30. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002; 20:2423-2428.
31. Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15 (Suppl.):S67-S75.
32. Heise T, Rave K, Weyer C, Heinemann L. Measurement of insulin sensitivity with the euglycaemic clamp technique: methodological pitfalls. Int J Diabetes 1998; 6:70-75.
33. Groop LC, Widen E, Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 1993; 36:1326-1331.
34. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27:484-490.
35. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
36. Nichols WW, Singh BM. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol 2002; 17:543-551.
37. Siebenhofer A, Kemp C, Sutton A, Williams B. The reproducibility of central aortic blood pressure measurements in healthy subjects using applanation tonometry and sphygmocardiography. J Hum Hypertens 1999; 13:625-629.
38. Lind L, Pettersson K, Johansson K. Analysis of endothelium-dependent vasodilation by use of the radial artery pulse wave obtained by applanation tonometry. Clin Physiol Funct Imaging 2003; 23:50-57.
39. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
40. Sawicki PT, Berger M. Hyperinsulinemia and hypertension - a myth? [in German]. Münch med Wschr 1992; 134:441-443.
41. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241.
42. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926.
43. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metab Res 1999; 31:418-423.
44. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-2410.
45. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6:45-86.
46. Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J. Captopril and insulin sensitivity [Letter]. Ann Intern Med 1985; 102:134-135.
47. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991; 34:119-125.
48. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
49. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
50. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11:43-50.
51. Budnitz D, Neuman WR. Underuse of beta-blockers following myocardial infarction. JAMA 2001; 285:1013.
52. Bakris GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, et al. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications 2005; 19:74-79.